Clinical Trials on Non Small Cell Lung Cancer (NSCLC) in Taiwan

Total 533 results

Ariad Pharmaceuticals

Completed

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)

Carcinoma | Lung Cancer | Non-small Cell Lung Cancer | Advanced Malignancies

United States, Canada, Germany, Spain, Taiwan, Korea, Republic of, Switzerland, Hong Kong, Singapore, Italy, Sweden, United Kingdom, France, Netherlands, Denmark, Australia, Norway, Austria, Luxembourg
Chang Gung Memorial Hospital

Unknown

Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients (QSYQT)

Carcinoma, Non-Small-Cell Lung

Taiwan
Amgen

Active, not recruiting

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Finland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)

Non-Small Cell Lung Cancer

China, Spain, Canada, Israel, Italy, Japan, Korea, Republic of, Taiwan, Australia, Poland, Brazil, Turkey, Belgium, Singapore, Czechia, Romania, Germany, Russian Federation, Greece, Netherlands, Argentina, France, Hong Kong, Mexico, Ukr... and more
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, United Kingdom, Canada, Hungary, Poland, Thailand, Germany, Korea, Republic of, Czechia, Japan, Philippines, Taiwan, Singapore, Austria
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center; National Taiwan University Hospital; Duke... and other collaborators

Terminated

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Taiwan, Germany, Belgium, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Non-small Cell Lung Cancer

China, Israel, United States, Australia, Canada, Colombia, Estonia, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Turkey, Ukraine
Jiangsu Simcere Pharmaceutical Co., Ltd.
G1 Therapeutics, Inc.

Completed

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

Extensive-stage Small-cell Lung Cancer

China
Regeneron Pharmaceuticals
Sanofi

Terminated

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Advanced Non-Small Cell Lung Carcinoma

United States, Belgium, France, Germany, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Lung Cancer

United States, Hungary, Spain, Ireland, Italy, Taiwan, Korea, Republic of, United Kingdom, Turkey, Canada, Israel, Australia, Mexico, Russian Federation
AstraZeneca
Arcus Biosciences, Inc.

Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

Non-Small Cell Lung Cancer

Korea, Republic of, Philippines, United States, Belgium, Hungary, India, Norway, United Kingdom, France, Canada, Germany, Japan, Malaysia, Taiwan, Greece, Italy, Mexico, Turkey, South Africa, Chile, Brazil, Romania, Spain, Switzerland, ... and more
GlaxoSmithKline

Active, not recruiting

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

Argentina, Korea, Republic of, Taiwan, France, Spain, Italy, United States, Germany, Romania, Poland, Brazil, Chile
AstraZeneca

Active, not recruiting

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3)

Anticancer Treatment

United States, France, Germany, Spain, Sweden, United Kingdom, Canada, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, China, Taiwan, Hong Kong, Netherlands, Australia, Mexico
Novartis Pharmaceuticals

Terminated

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer (ATRACT-1)

Non-Small Cell Lung Cancer

United States, Greece, Hong Kong, Taiwan, Argentina, Germany, United Kingdom, Singapore, Italy, Spain, France, Korea, Republic of, Netherlands, Brazil, Canada, Turkey, China, New Zealand, Hungary, Poland, Australia, Japan, Israel, Bel... and more
Eli Lilly and Company

Completed

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

China, Italy, Australia, Poland, Netherlands, India, Austria, Spain, Bulgaria, United States, Greece, Turkey, Brazil, Croatia, Czech Republic, Germany, Hungary, Korea, Republic of, Romania, Taiwan
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru
AstraZeneca

Recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

Non-Small Cell Lung Cancer

China, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
Pfizer

Active, not recruiting

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Non-small-cell Lung Cancer | Advanced Malignancies

China, Korea, Republic of, Taiwan, Japan, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Canada, Taiwan, United States, Italy, Korea, Republic of, Thailand, Belgium, Germany, Austria, Turkey, Greece, United Kingdom, Colombia, India, Malaysia, Brazil, Spain, Poland, Bulgaria, Australia, Czechia, Lebanon, Netherlands, Russian...
Hoffmann-La Roche

Completed

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Italy, Belgium, Israel, Sweden, China, Hong Kong, Australia, Colombia, Romania, Germany, Ireland, Mexico, Korea, Republic of, Taiwan, Turkey, Russian Federation, Czech Republic, Hungary, Netherlands, New Zealand, Peru, Finland, Austria and more
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Belgium, China, France, Netherlands, Japan, Hungary, Russian Federation, Taiwan, Ireland, Romania, Israel, Latvia, Italy, Portugal, Austria, Bulgaria, Chile, Ukraine, Argenti... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
AstraZeneca

Active, not recruiting

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

Non-Small Cell Lung Cancer

Belgium, Italy, Spain, United States, Poland, India, Taiwan, Thailand, Vietnam, Canada, France, Germany, Korea, Republic of, Brazil, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation, China, Austria, Chile, Netherlands, Bulg... and more
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

Australia, Belgium, France, Italy, Hong Kong, Canada, Denmark, Taiwan, Russian Federation, United Kingdom, Spain, Hungary, Czech Republic, Poland, Germany, Netherlands
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Germany, Italy, Spain, Canada, Poland, Thailand, Vietnam, Korea, Republic of, Hungary, Japan, Mexico, Peru, Turkey, United Kingdom, Taiwan, Chile, Australia, Israel, South Africa, Netherlands, Greece, Sin... and more
Hoffmann-La Roche

Active, not recruiting

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Non-Small Cell Lung Cancer

United States, Spain, Italy, Taiwan, Belgium, China, Hong Kong, Japan, Germany, Canada, Israel, Russian Federation, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Ukraine, Romania, Australia, Hungary, Portugal
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

KRAS Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Pfizer

Completed

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Non-Small Cell Lung Cancer

Germany, Spain, Greece, Korea, Republic of, India, United States, Netherlands, Taiwan, Japan, Hungary, Russian Federation, Philippines, Poland, Australia, Brazil, Croatia, South Africa, Turkey, Romania, Chile, Ukraine, Bulgaria, Cze... and more
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
Canadian Cancer Trials Group
National Health and Medical Research Council, Australia; Dutch Society of Physicians... and other collaborators

Active, not recruiting

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Non-Small Cell Lung Cancer

Canada, United States, France, Spain, Taiwan, China, Australia, Italy, Japan, Singapore, Korea, Republic of, New Zealand, Netherlands, Romania, Bulgaria, Brazil, Hungary, Poland, Ukraine
National Taiwan University Hospital
National Science Council, Taiwan

Completed

Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients

Non-small-cell Lung Cancer

Taiwan
Novartis Pharmaceuticals

Terminated

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Non-Small Cell Lung Cancer

United States, Germany, Canada, France, Spain, Japan, Taiwan, Italy, Argentina, Austria, Poland, Russian Federation, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, Greece, Israel, Slovenia, Switzerland, ... and more
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Korea, Republic of, United States, Japan, Brazil, Taiwan, Australia, Austria, Canada, Poland, Belgium, United Kingdom, Turkey, Hungary, Germany, India
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States, Guam
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Limited Stage Small Cell Lung Cancer

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)

Non-Small Cell Lung Cancer

Canada, Belgium, Korea, Republic of, United States, France, Brazil, China, New Zealand, Israel, Spain, Argentina, Serbia, Mexico, Italy, Japan, Turkey, Taiwan, Costa Rica, Thailand, Australia, Germany, Hong Kong, Netherlands, Peru, Poland, Russian Federation and more
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
GlaxoSmithKline

Terminated

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, Australia, Canada, Netherlands, Finland, Taiwan, Czechia, Estonia, Spain, Argentina, Belgium, France, Sweden, Germany, Israel, Italy, Korea, Republic of, Singapore, Ukraine, United Kingdom, Austria, Ireland, Thailand, C... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Non-Small Cell Lung Cancer

Poland, United States, Brazil, France, Guatemala, Hungary, Japan, Korea, Republic of, Peru, Romania, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, Spain, Taiwan, Germany, Netherlands, Singapore, Austria, Japan, Australia, France, Russian Federation, Sweden, Thailand, Korea, Republic of, Lebanon, Norway, United Kingdom, China, India, Brazil, Turkey, Poland, Denmark, Greece, ... and more
Novartis Pharmaceuticals

Completed

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Anaplastic Thyroid Cancer | Other Solid Tumors | Non-small Sell Lung Cancer (NSCLC)

United States, Italy, Spain, Hungary, Taiwan, Germany, Netherlands, France, Norway, Poland, Thailand, Lebanon, Turkey, Canada
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Japan, Mexico, Poland, Romania, Russian Federation, Spain, United Kingdom
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
Bristol-Myers Squibb

Withdrawn

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

Italy, Korea, Republic of, Turkey, Canada, Spain, Australia, Mexico, Taiwan, France, Germany, Switzerland, Greece, Japan, Austria, United States, Brazil, Czechia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States

Clinical Trials on Non Small Cell Lung Cancer (NSCLC) in Taiwan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations